American Journal of Hematology publishes positive results of Phase III trial of Tavalisse to treat chronic immune thrombocytopenia . Rigel Pharma.
Rigel Pharmaceuticals, Inc. announced that the American Journal of Hematology has published positive results from the Fostamatinib in Thrombocytopenia (FIT) Phase III clinical program of Tavalisse (fostamatinib disodium hexahydrate) for the treatment of adults with chronic immune thrombocytopenia (ITP). The study, "Fostamatinib for the Treatment of Adult Persistent and Chronic Immune Thrombocytopenia: Results of Two Phase III, Randomized, Placebo-Controlled Trials," is available on the journal website.
On April 17, 2018 , the FDA approved Tavalisse for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. "These data demonstrate that Tavalisse offers the potential for a rapid, robust and durable platelet response, which is why we are excited to soon make it available to the population of patients in need of alternate treatment options," said Anne-Marie Duliege, M.D., Chief Medical Officer of Rigel Pharmaceuticals, Inc. "Tavalisse is the first approved treatment option that targets the SYK pathway, which is the main pathway involved in platelet destruction in ITP."
See- Fostamatinib for the Treatment of Adult Persistent and Chronic Immune Thrombocytopenia: Results of Two Phase III, Randomized, Placebo?Controlled Trials"- James Bussel MD Donald M. Arnold MD Elliot Grossbard MD Ji?� Mayer MD et.al., First published: 26 April 201 .https://doi.org/10.1002/ajh.25125.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins